The study focused on lac-phe, a molecule naturally produced by the body during vigorous physical activity and known to suppress appetite and regulate energy metabolism. Scientists observed that metformin significantly elevated lac-phe levels in prostate cancer patients, suggesting the drug activates a biological pathway typically triggered by exercise. The research was conducted as part of a clinical trial examining metformin's effects in men receiving androgen deprivation therapy, commonly known as hormone therapy.
Hormone therapy is a standard treatment for prostate cancer but is associated with a range of metabolic complications, including increased body fat, insulin resistance, and loss of muscle mass. These side effects can worsen a patient's overall health and quality of life, and regular vigorous exercise is widely recommended to counteract them. However, many prostate cancer patients are unable to maintain high levels of physical activity due to fatigue, age, or other health conditions, making the discovery of a potential pharmaceutical alternative especially relevant.
Lead researchers noted that the elevation of lac-phe by metformin suggests the drug may be engaging a gut-brain signaling pathway that mirrors the body's response to intense exercise. This pathway is believed to play a role in regulating appetite and reducing caloric intake, which could explain some of the metabolic benefits observed in patients taking the drug. Scientists cautioned, however, that the findings represent early-stage research and do not suggest that metformin can fully replace the broad health benefits of physical activity.
The study adds to a growing body of evidence supporting metformin's potential role beyond its established use in managing type 2 diabetes. Previous research has indicated the drug may have anti-cancer properties, though its precise mechanisms in oncology settings continue to be studied. Researchers said the new findings provide a more specific biological explanation for how metformin may benefit prostate cancer patients metabolically, and called for further clinical trials to confirm and expand on the results.
Prostate cancer is one of the most commonly diagnosed cancers among men globally, and hormone therapy remains a cornerstone of treatment for advanced cases. The research team indicated that understanding how drugs like metformin interact with exercise-linked biological pathways could help clinicians develop more targeted supportive care strategies. Further studies are expected to investigate whether the elevated lac-phe levels translate directly into measurable improvements in patient weight management, energy levels, and long-term cancer outcomes.
